Cyclo Therapeutics (CYTH) PT Lowered to $0.95 at Ascendiant Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. ETSY

Go back to Cyclo Therapeutics (CYTH) PT Lowered to $0.95 at Ascendiant Capital

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

August 22, 2024 6:50 AM EDT

Cyclo Therapeutics TransportNPC Phase 3 clinical trial for Trappsol® Cyclo for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025

NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (Nasdaq: CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus... More